Zolbetuximab represents a exciting therapeutic strategy for people with certain types of colorectal tumor. This monoclonal treatment directly affects glypican-3 (GPC3), a molecule frequently overexpressed on tumor https://www.targetmol.com/compound/zolbetuximab